SureTrader Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 6/24/2016 11:08:04 PM - Followers: 165 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: Annual Report to Security Holders (ars) 06/09/2016 06:13:09 AM
CVM News: Proxy Statement (definitive) (def 14a) 06/09/2016 06:02:47 AM
CVM News: CEL-SCI Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Neck Cancer Trial 06/01/2016 08:11:00 AM
CVM News: CEL-SCI to Present at the Fifth Annual Marcum MicroCap Conference 05/31/2016 09:00:00 AM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/20/2016 01:50:28 PM
PostSubject
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#7359  Sticky Note News! Ergomed Increases Its Co-Development Contribution up to $12,000,000 trickledownfacists 10/05/15 08:40:16 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#8308   It'll be better than 19 trickledownfacists 06/24/16 11:08:04 PM
#8307   if we don't improve our numbers next week Turney 06/24/16 08:42:51 PM
#8306   Numbers next week, getting close. trickledownfacists 06/24/16 06:24:34 PM
#8305   Ahhhh! Foxwoods Man 06/24/16 04:21:56 PM
#8304   Sarcasm..... trickledownfacists 06/24/16 03:42:12 PM
#8303   Just recovering what CVM lost yesterday...I really doubt Foxwoods Man 06/24/16 03:36:30 PM
#8302   Who would have thought, Brexit good for cel-sci. trickledownfacists 06/24/16 03:20:59 PM
#8301   No kidding! rough 30 years plus. ducruacuteo11 06/24/16 03:02:58 PM
#8300   Rough week trickledownfacists 06/23/16 05:14:46 PM
#8299   Vote accordingly trickledownfacists 06/23/16 01:29:41 PM
#8298   That is how I feel also. steve2150 06/23/16 01:00:14 PM
#8297   It will be another 10 years before you ducruacuteo11 06/23/16 10:52:28 AM
#8296   Undervalued Been here 10+ years, bought at about $1.74 steve2150 06/21/16 06:46:25 PM
#8295   Ergomed can't afford to let us fail to Turney 06/20/16 09:00:53 PM
#8294   "Phase 3 Head & Neck Cancer Trial Numerous ducruacuteo11 06/20/16 03:27:42 PM
#8293   CVM News: Annual Report to Security Holders (ars) 06/09/2016 mick 06/19/16 12:57:13 PM
#8292   Cel-Sci Corp. ($0.00 (CVM) mick 06/19/16 12:57:00 PM
#8291   Dear Fellow Shareholders: As CEL-SCI shareholders most of you trickledownfacists 06/17/16 10:06:11 PM
#8290   Have you tried reaching out to Dr. Joel Palefsky? trickledownfacists 06/17/16 09:08:12 PM
#8289   Almost 220 days per patient for results to trickledownfacists 06/17/16 09:06:27 PM
#8288   From the university website. I have emailed trickledownfacists 06/17/16 08:55:41 PM
#8287   Head of the University of San Fran immunotherapy trickledownfacists 06/17/16 08:39:15 PM
#8286   Quite the sale after hours... trickledownfacists 06/17/16 04:27:48 PM
#8285   Has anyone heard from Gavin or receive any trickledownfacists 06/17/16 01:27:20 PM
#8284   I'm waiting for any news release or announcement trickledownfacists 06/16/16 01:24:47 PM
#8283   Much like everything else that is brewing around drkazmd65 06/16/16 01:23:27 PM
#8282   Correct. It was mentioned a while ago that Foxwoods Man 06/16/16 11:35:19 AM
#8281   Geert's letter to shareholders that accompanied the Annual Paleman 06/16/16 09:51:31 AM
#8280   stockcharts.com/c-sc/sc?s=CVM&p=D&yr=0&mn=6&dy=4&i=p88035872529&a=3701730 mick 06/15/16 11:03:48 AM
#8279   I think I remember 2 million or so Foxwoods Man 06/14/16 03:02:53 PM
#8278   Seems like we are going to have a Kami_ss 06/14/16 11:12:33 AM
#8277   FM, It has only been 30 plus years. LOL. ducruacuteo11 06/13/16 06:49:16 PM
#8276   Yup trickledownfacists 06/11/16 08:51:29 AM
#8275   Geert may be a part of the low Foxwoods Man 06/11/16 07:11:53 AM
#8274   Yes, everytime he opens his mouth we go steve2150 06/10/16 07:30:41 PM
#8273   What did I tell you? LOL! ducruacuteo11 06/09/16 11:56:44 AM
#8272   NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE trickledownfacists 06/09/16 09:11:27 AM
#8271   Oh that's a sure thing! lol Kami_ss 06/08/16 10:50:53 AM
#8270   Tomorrow, Geert will present again. I guarantee ducruacuteo11 06/07/16 07:02:36 PM
#8269   VIENNA, VA / ACCESSWIRE / June 7, 2016 trickledownfacists 06/07/16 03:36:00 PM
#8268   816 trickledownfacists 06/06/16 05:14:45 PM
#8267   Does anybody know how many patients we have ducruacuteo11 06/06/16 04:56:03 PM
#8266   I don't listen to the conferences anymore. It Foxwoods Man 06/03/16 07:15:45 AM
#8265   Anyone hear the conference or have a replay link? trickledownfacists 06/02/16 02:47:02 PM
#8264   I hope you are right! Maybe that's ducruacuteo11 06/02/16 02:34:07 PM
#8263   I'm a bit more positive on that. If Kami_ss 06/02/16 01:23:14 PM
#8262   I don't agree. They still average about 30 ducruacuteo11 06/02/16 12:12:22 PM
#8261   Sooner than that but a little later than expected. trickledownfacists 06/01/16 01:24:47 PM
#8260   Summer holiday in Europe again. LOL. ducruacuteo11 06/01/16 11:57:43 AM
#8259   I doubt the enrollment would have anything to pijoe 06/01/16 08:55:25 AM
PostSubject